SOLICITATION NOTICE
65 -- Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program - RFQ Appendices - RFQ HT9402-18-Q-0006 - November 2018 P&T Industry Reporting
- Notice Date
- 8/7/2018
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- Other Defense Agencies, Defense Health Agency, Contracting Office - Aurora, 16401 E. CenterTech Pkwy., Aurora, Colorado, 80011, United States
- ZIP Code
- 80011
- Solicitation Number
- HT9402-18-Q-0008
- Point of Contact
- Yvette H. Dluhos,
- E-Mail Address
-
yvette.h.dluhos.civ@mail.mil
(yvette.h.dluhos.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- November 2018 P&T Industry Reporting Data RFQ HT9402-18-Q-0008 for FY19 Q1 November 2018 P&T Appendix Neurological Agents Miscellaneous - Movement Disorders Appendix Gastrointestinal 2 Agents - CIC and IBS-C Appendix Gastrointestinal 2 Agents - Miscellaneous Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: November 2018: The following drug classes/subclass and agents will be reviewed: GASTROINTESTINAL-2 AGENTS, SUB CLASS: MISCELLANEOUS: Alinia, Dificid, Lotronex, Viberzi, Xifaxan GASTROINTESTINAL-2 AGENTS, SUB CLASS: CIC AND IBS-C: Amitiza, Linzess, Trulance NEUROLOGICAL AGENTS MISCELLANEOUS, SUB CLASS: MOVEMENT DISORDERS: Austedo, Ingrezza, Xenazine RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein. The historical utilization data including quantity dispensed and 30 day equivalents by mouth is also attached herein. PRE-Proposal Conference: See Paragraphs 2.4 and 2.5 of the RFQ. Minutes will be posted herein. CLINICAL PRESENTATIONS: Interested parties or potential offerors may provide clinical presentations. To schedule, call 1-210-536-6116. Clinical presentations must be made available on CD (not retained by POD San Antonio staff) at time of presentation. Flash drives are not authorized for use on DoD computers. We are also requesting a dossier. A few weeks prior to the meeting, we will send you a list of detailed questions. POCs: See below and paragraph 2.3 of the RFQ. POCs: Part 2.3 of the RFQ. For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/331c19cf2477dd3478692b8676341be9)
- Place of Performance
- Address: Defense Health Agency, Contracting Office - Aurora, 7800 IH-10 West, Ste 400, San Antonio, Texas, 78230, United States
- Zip Code: 78230
- Zip Code: 78230
- Record
- SN05024877-W 20180809/180807231545-331c19cf2477dd3478692b8676341be9 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |